Engineered immune cells take on childhood cancers that Won't quit
NCT ID NCT07358260
First seen Jan 24, 2026 · Last updated May 01, 2026 · Updated 8 times
Summary
This early-stage study tests a new treatment called B7-H3 CAR T cells in 40 children and young adults whose solid tumors have come back or stopped responding to standard care. The therapy uses the patient's own immune cells, modified to target a marker called B7-H3 found on many cancer cells. The main goals are to see if the cells can be made successfully and to find the safest dose.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PEDIATRIC SOLID TUMOR are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Dana Farber Cancer Institite
Boston, Massachusetts, 02115, United States
Conditions
Explore the condition pages connected to this study.